Narcolepsy is a chronic brain disorder and the second largest cause of excessive daytime sleepiness in the United States, Europe, and Japan. It can cause people to sleep any time. Majority of narcolepsy patients suffer from cataplexy – a sudden weakness of muscles, triggered by emotions. According to the Narcolepsy Networks (NN), narcolepsy affects one in every 2000 people in the United States.
For Market Research Report on “Narcolepsy Therapeutics Market” Visit -http://www.grandviewresearch.com/industry-analysis/narcolepsy-therapeutics-market
The narcolepsy therapeutics market stood at USD 990 million in 2014. It is estimated to attain around USD 1.99 billion by 2020, at 11.9% CAGR from 2014 to 2020 (forecast phase). Reimbursement policies favoring narcolepsy therapy will increase market demand over the said phase.
The market is divided into kinds on the basis of cataplexy prevalent narcolepsy, non cataplexy, and secondary narcolepsy. Cataplexy prevalent narcolepsy gained a share above 50% in 2014. Non-cataplexy would witness 12.3% CAGR in the future. Increasing medical expenses on the diagnosis of narcolepsy and its treatment should favor this segment.
The narcolepsy therapeutics market has various drugs for treating the disease and its symptoms. The drugs include sodium oxybate, Selective Serotonin Reuptake Inhibitors (SSRIs), tricyclic antidepressants, and others. Sodium oxybate dominated the market in 2014 and had more than 78% share. It is predicted to register a CAGR of 13.5% in the forecast phase.
This is due to its coverage by medical reimbursement policies and high prices. SSRIs and tricyclic antidepressants will face declining incomes due to presence of more specific treatment drugs approved by the Food and Drug Administration.
In terms of regions, Europe had the largest narcolepsy therapeutics market in 2014, with revenues reaching USD 375.3 million. It would reach nearly USD 736.5 million by 2020, growing at a CAGR of 11.4% during the aforementioned phase. Asia Pacific would undergo a CAGR of about 13% in the future. This can be attributed to investments in biotechnology and pharmaceutical companies in the region.
Key players in the worldwide narcolepsy therapeutics market comprise Jazz Pharmaceuticals Plc, Arena Pharmaceuticals, Graymark Healthcare, Inc., Addrenex Pharmaceuticals, and Ligand Pharmaceuticals. ‘Xyrem’ is an FDA approved drug to treat the disease. Jazz Pharmaceuticals, the manufacturer of this drug, offers coupons (through its assistance program) to patients unable to afford medical coverage.
Information Source: Grand View Research